Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

Inclusion Criteria:

- Asthma diagnosed by a respiratory physician greater than or equal to (>/=) 12 months
prior to study enrolment

- Pre-bronchodilator FEV1 of 30 percent (%) to 85% at baseline/Visit 1

- Documented bronchodilator response defined as >/=12% relative improvement in FEV1
after bronchodilator administration or a positive methacholine bronchial challenge
test with provocative concentration causing a 20% fall in FEV1 (PC20) less than (<) 8
milligrams (mg) at study baseline/Visit 1 or within 24 months prior to baseline

- Current treatment with a total daily dose of >/= 500 micrograms (mcg) of fluticasone
propionate (FP) dry powder inhaler (DPI) (or equivalent ) and at least one of the
following controller medications: long-acting Beta-agonist (LABA), leukotriene
receptor antagonist (LTRA), long-acting muscarinic antagonists (LAMAs), theophylline
or oral corticosteroids, with a continued duration of three months prior to
baseline/Visit 1

Exclusion Criteria:

- Acute or chronic parasitic, bacterial, fungal or viral infections that required, or
currently require, hospitalization or antimicrobial treatment during the last four
weeks prior to participant eligibility

- Acute asthma exacerbation or any other medical event treated with increased doses of
oral, or any dose of intramuscular (IM) or intravenous (IV) corticosteroids within six
weeks prior to study

- Other relevant pulmonary diseases (e.g. chronic obstructive pulmonary disease,
idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension,
tuberculosis) requiring treatment within 12 months prior to baseline/Visit 1

- Ex-smokers with >/=10 pack-year smoking history

- Prior treatment with bronchial thermoplasty

- Participation in any clinical trial of an investigational agent or procedure within
six months prior to baseline/Visit 1 or during the study

- Pregnancy prior to participation or during the study